Search for content, post, videos

Novo Nordiskt to invest more than 17 billion DKK in manufacturing facilities

Novo Nordisk

Novo Nordisk has announced plans to invest more than 17 billion Danish kroner in construction of three new manufacturing facilities as well as expansion of one existing facility at its production site in Kalundborg, Denmark.​

The investment will establish additional capacity across the entire global value chain from manufacturing of active pharmaceutical ingredients (API) to assembly and packaging, with the vast majority being invested in API capacity, states the company. These expansions will provide capacity for the production of Novo Nordisk’s current and future oral and injectable products.​ The new facilities will be automated and include state-of-the-art production technologies, describes Novo Nordisk.

“The investment announced today emphasizes our continued commitment to Denmark and Kalundborg being at the heart of our global manufacturing setup.”

“This major investment in our manufacturing facilities in Kalundborg is an important step in building and ensuring future capacity for production of our current and future oral and injectable product portfolio. Kalundborg is currently the cornerstone in our production of API and the expansion of the manufacturing capacity is important to meeting the future demands of patients. The investment announced today emphasizes our continued commitment to Denmark and Kalundborg being at the heart of our global manufacturing setup,” says Henrik Wulff, EVP, Product Supply, Quality & IT, Novo Nordisk. ​

Create around 400 new jobs

The investment projects are expected to be finalized in 2027 and will create around 400 new jobs. More than 2,500 external staff will be engaged in the building phase. ​

Novo Nordisk manufacturing in Kalundborg​

Novo Nordisk’s production facilities in Kalundborg were established in 1969. Today, the facilities cover an area of 1,200,000 m2 and employ about 3,200 people. In Kalundborg, Novo Nordisk manufactures products for the treatment of obesity and diabetes as well as several biopharmaceutical products. Since the turn of the millennium and until today, Novo Nordisk has invested more than 18 bn Danish kroner in the production facilities in Kalundborg. The investment announced today almost doubles 20 years of investments.

Image: API purification factory. Part of an overall project in Kalundborg. Entire project expected to be completed in 2027.